Q-omics provides the consensus-scored MIR574 profile across patient tissues and cancer cell-line models. MIR574 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, MIR574 is differentially expressed in 7, with the highest sampling consensus in BRCA. Additionally, MIR574 RNA expression shows 11,586 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight CHOL, BRCA, and UVM as cancer lineages where MIR574 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR574 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR574 survival associations across molecular data types. MIR574 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR574 RNA expression–survival associations across cancer types. High MIR574 expression shows unfavorable associations in CHOL, COAD, ACC, LUSC, THCA and KIRP. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CHOL as the clearest survival context for MIR574 RNA expression.
This table summarizes MIR574 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR574. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR574 shows lower tumor expression in LUSC and higher tumor expression in BRCA, LUAD, KIRP, KIRC and LIHC. The BRCA box plot shows higher MIR574 RNA expression in tumor versus normal tissue (log2 FC = +0.516, t-test p < 0.001).
This table shows molecular features associated with MIR574 in patient tissues and cancer cell lines. In patient samples, MIR574 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
